SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GPSite who wrote (14)6/3/1999 8:23:00 PM
From: glen  Read Replies (1) of 250
 
GP-YOU SAID IN POST #14, "The FDA wants to play ball. They set the efficacy level for approval at 30% -- a level that should be a slam-dunk for VaxGen's AIDSVAX. Why did they do that? Because the FDA wants to make it happen"

There are some real answers as to why the FDA would give approval with as little as a 30% efficacy level. First, there is at this time no known cure for AIDS. Although great strides have been made in prolonging the life expectancy of those infected, all will eventually succomb. The cost to society in lost lives and, in dollars spent for research and providing health care, is absolutely staggering...just enormous. If only 3 out of every 10 people vaccinated became immune ti the HIV virus, then the benefits and savings would be in the hundresd of millions of dollars, if not billions. It is much less expensive for a governments/society to help underwrite the cost of a vaccination program than it is to have to provide years of medical care to AIDS victims.

So, if VaxGen wins FDA approval, the upside potential is dazzling with an instant worldwide market that would easily take VaxGen's share price into triple digits.

Where would you venture to guess this re-opens in the secondary market?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News